Articles related to CLINICAL STUDY

The master cell growth regulator mTORC1 is known to be hyperactive in colon cancer. This study shows that in mice, a low protein diet blocked mTORC1’s nutrient signaling pathway, stopping the cancer from growing and leading to increased cancer cell death.

Versus placebo, pemafibrate yielded a more than 25% greater reduction in triglycerides, VLDL, remnant cholesterol, and apolipoprotein C-III in patients with type 2 diabetes. However, there was no reduction versus placebo in MI, ischemic stroke, need for coronary revascularization, or CV death.

Some of the key findings of this meta-analysis of antiviral therapy in the outpatient setting include: (treatment vs no-treatment) Probable reduction of hospitalization with Nirmatrelvir–ritonavir and casirivimab–imdevimab (1% vs 6%) Probable reduction in all-cause mortality with Nirmatrelvir–ritonavir (0% vs 1%) Probable improved recovery with regdanvimab (87% vs 72%) Four-day reduction in time to recovery with casirivimab-imdevimab Possible reduction in recovery rates with hydroxychloroquine

In this trial involving 29 healthcare facilities in 4 countries from May 2020 through April 2022, PCR-confirmed COVID infection occurred in approximately 10.5% of the mask group versus approximately 9.3% of the N95 group.

In this cohort study of insurance data over an 18-year period covering more than 15,000 pregnancies that involved methadone or buprenoprine use, buprenorphine in pregnancy was associated with a lower risk of adverse neonatal outcomes versus methadone use. However, the risk of adverse maternal outcomes was similar.

Trial participants were instructed on imagery rehearsal therapy — rewriting their recurring nightmare to end on a positive note and then rehearsing that story. Next, targeted memory reactivation was used to link a sound to that positive version of the dream. Those in the study reduced their nightmares from an average of almost 3 per week, to just one every five weeks.